Negotiations between the National Health Insurance Service (NHIS) and pharmaceutical companies have been completed for 5 morning sickness drugs, hepatitis B drug Vemlidy Tab (tenofovir alafenamide hemifumarate), and Chinese company BeiGene Korea's new cancer drug Brukinsa Cap (zanubrutinib).

The 5 morning sickness drugs underwent new drug pricing negotiations, Vemlidy underwent the price-volume agreement negotiations, and Brukinsa underwent a negotiation to expand its scope of use.

According to the industry on the 17th, the NHIS recently updated its list of drugs completed negotiations and announced the completion of negotiations of the drugs listed above.

The 5